DLL3-targeted PET/CT scan for neuroendocrine cancer
Part of Cancer clinical trials.
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with, or are suspected to have, neuroendocrine carcinoma (a cancer affecting certain hormone-making cells).
- Your blood levels of ProGRP or NSE (two markers used to track this cancer) are at least 3 times the normal upper limit.
- You are willing and able to provide written informed consent (or have a legal guardian do so).
- Your doctor expects you to live for more than 3 months, and you can follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan to look for a protein called DLL3 in small cell lung cancer. The scan may help doctors better see and understand the cancer. You may be able to join if you have suspected or confirmed small cell lung cancer and certain blood markers are high.
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
This early-phase trial tests a new radioactive drug that targets a protein (DLL3) found on some lung and prostate cancer cells. It aims to see if this drug is safe and effective for patients whose cancer has progressed after standard treatment.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.